Home Cart Sign in  
Chemical Structure| 19057-60-4 Chemical Structure| 19057-60-4

Structure of Dioscin
CAS No.: 19057-60-4

Chemical Structure| 19057-60-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Dioscin, a natural product isolated and purified from the rhizome of Dioscorea Zingiberensis C.H.Wright, is a potent ITGA5 inhibitor, showing potent anti-cancer effect against a variety of tumor cell lines.

Synonyms: CCRIS 4123; Collettiside III; Saponin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Dioscin

CAS No. :19057-60-4
Formula : C45H72O16
M.W : 869.04
SMILES Code : C[C@@]12[C@]3([H])[C@](O[C@]4(CC[C@@H](C)CO4)[C@H]3C)([H])C[C@@]1([H])[C@@]5([H])[C@]([C@@]6(C(C[C@@H](O[C@@]7([H])[C@@H]([C@H]([C@H](O[C@@]8([H])[C@@H]([C@@H]([C@@H](O)[C@H](C)O8)O)O)[C@@H](CO)O7)O)O[C@@]9([H])[C@@H]([C@@H]([C@@H](O)[C@H](C)O9)O)O)CC6)=CC5)C)([H])CC2
Synonyms :
CCRIS 4123; Collettiside III; Saponin
MDL No. :MFCD02094174
InChI Key :VNONINPVFQTJOC-ZGXDEBHDSA-N
Pubchem ID :119245

Safety of Dioscin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Dioscin

cytoskeleton

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human periodontal ligament stem cells (hPDLSCs) 1 μg/mL and 3 μg/mL 1 day and 3 days Dioscin promoted osteogenic differentiation of hPDLSCs under LPS-induced inflammatory conditions, increasing the expression of osteogenic markers and the formation of mineralized nodules. PMC10878154
HT29 cells 2 μM 12 hours Screening of a natural product library revealed that Dioscin significantly inhibited glycolysis in HT29 cells. PMC7000337
SK-MES-1 0, 1.25, 2.5, 5, 10 μM 24 h and 48 h Dioscin significantly inhibited the proliferation of lung SCC cells, with an IC50 value of 2.05 μM at 48 h. PMC7545707
NCI-H520 0, 1.25, 2.5, 5, 10 μM 24 h and 48 h Dioscin significantly inhibited the proliferation of lung SCC cells, with an IC50 value of 4.59 μM at 48 h. PMC7545707
HBE 0, 1.25, 2.5, 5, 10 μM 24 h and 48 h Dioscin had a weaker inhibitory effect on HBE cells, with an IC50 value of 8.47 μM at 48 h. PMC7545707
MC3T3-E1 cells 0.25 μg/ml, 0.5 μg/ml, 1.0 μg/ml 24 h, 48 h, 72 h Dioscin significantly promoted the proliferation of MC3T3-E1 cells in a dose-dependent manner at 48 h and 72 h. PMC4014146
MG-63 cells 0.25 μg/ml, 0.5 μg/ml, 1.0 μg/ml 24 h, 48 h, 72 h Dioscin significantly promoted the proliferation of MG-63 cells in a dose-dependent manner at 48 h and 72 h. PMC4014146
H9C2 cells 50, 100, 200 ng/mL 24 hours To investigate the protective effect of Dioscin against DOX-induced H9C2 cell injury, the results showed that Dioscin significantly increased cell viability and improved cell morphology PMC5953242
RAW264.7 cells 37.5, 75, 150, 300, 600, 1200, 2400 ng/mL 24 hours To evaluate the effect of Dioscin on the viability of RAW264.7 cells, results showed that Dioscin had no significant effect on cell viability within the concentration range. PMC5695011
NIH-3T3 cells 125, 250, 500, 1000, 2000, 4000, 8000 ng/mL 24 hours To evaluate the effect of Dioscin on the viability of NIH-3T3 cells, results showed that Dioscin had no significant effect on cell viability within the concentration range. PMC5695011
U2OS and 143B cells 2.5 μM 24 hours Dioscin induced G2/M phase arrest PMC5832770
SMMC7721 cells 1.4, 2.9, 5.8 μM 24 hours Dioscin significantly inhibited the proliferation, migration, and invasion of SMMC7721 cells, and induced apoptosis, autophagy, and DNA damage. PMC6433650
HepG2 cells 1.4, 2.9, 5.8 μM 24 hours Dioscin significantly inhibited the proliferation, migration, and invasion of HepG2 cells, and induced apoptosis, autophagy, and DNA damage. PMC6433650
NOZ cells 0, 1, 2, 4, 6, 8 μM 24h, 48h, 72h To evaluate the inhibitory effect of Dioscin on NOZ cell proliferation PMC5485633
SGC996 cells 0, 1, 2, 4, 6, 8 μM 24h, 48h, 72h To evaluate the inhibitory effect of Dioscin on SGC996 cell proliferation PMC5485633
293T cells 0, 1, 2, 4, 6, 8 μM 24h, 48h, 72h To evaluate the effect of Dioscin on 293T cells PMC5485633
NIH-3T3 cells 1000, 500, 250 ng/mL 30 minutes To evaluate the effect of Dioscin on the TGF-β/Smad3 signaling pathway in NIH-3T3 cells, results showed that Dioscin significantly inhibited the phosphorylation of Smad3. PMC5695011
Bone marrow-derived macrophages (BMDMs) 1 μg/mL and 3 μg/mL 4 hours Dioscin inhibited the LPS-induced elevation of Il1β, Il6, Tnfα, and Nlrp3 mRNA expression and reduced the secretion of IL-6 and TNF-α. PMC10878154
PC9GR cells 2.1μM 48 hours Dioscin inhibits cell viability and induces apoptosis in PC9GR cells PMC5821048
H1650 cells 1.7μM 48 hours Dioscin inhibits cell viability and induces apoptosis in H1650 cells PMC5821048
H1975 cells 4.3μM 48 hours Dioscin inhibits cell viability and induces apoptosis in H1975 cells PMC5821048
CL97 cells 4.1μM 48 hours Dioscin inhibits cell viability and induces apoptosis in CL97 cells PMC5821048
U2OS and 143B cells 2.5 μM 48 hours Dioscin significantly increased the proportion of apoptotic cells PMC5832770
RAW264.7 cells 300, 150, 75 ng/mL 6 hours To evaluate the effect of Dioscin on the secretion of pro-inflammatory cytokines in RAW264.7 cells, results showed that Dioscin significantly inhibited the secretion of IL-1β, IL-6, TNF-α, and MCP-1. PMC5695011
MH-S cells 200 nM, 400 nM, 800 nM Dioscin treatment reduced CS-induced apoptosis in MH-S cells and promoted autophagy. PMC6485284
Human Umbilical Vein Endothelial Cells (HUVECs) 1.25 mg/L and 5 mg/L Dioscin promoted endothelial cell proliferation, migration, and tube formation under hypoxic conditions, indicating its pro-angiogenic effects. PMC8282240

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rats and mice DOX-induced myocardial injury model Oral Rats: 60, 30, 15 mg/kg; Mice: 80, 40, 20 mg/kg Once daily for seven consecutive days To investigate the protective effect of Dioscin against DOX-induced myocardial injury, the results showed that Dioscin significantly improved ECG changes, reduced serum CK and LDH levels, and improved myocardial histopathological changes PMC5953242
C57BL/6 mice silicosis model Oral 20, 40, 80 mg/kg once daily for 56 days To evaluate the effect of Dioscin on pulmonary fibrosis in a silicosis mouse model, results showed that Dioscin significantly reduced collagen deposition and alleviated pulmonary fibrosis. PMC5695011
Nude mice Xenograft model Intraperitoneal injection 10 mg/kg Every two days, until the end of the experiment Dioscin delayed in vivo tumor growth, promoted Skp2 ubiquitination, and inhibited Skp2 expression. PMC7000337
C57BL/6J mice Ligation-induced periodontitis model Gingival injection 10 mg/kg Once every other day for 2 weeks Dioscin significantly reduced alveolar bone loss in ligation-induced periodontitis mice and suppressed the inflammatory response in periodontal tissues. PMC10878154
BALB/c-Nude mice NCI-H520 xenograft model Oral 80 mg/kg/day once daily for 12 days Dioscin significantly inhibited the growth of NCI-H520 xenograft tumors, with a significant reduction in tumor volume and weight, and induced tumor cell apoptosis. PMC7545707
C57BL/6 mice Myocardial Infarction Model Intragastric administration 40 µg/g Once daily for 2 weeks Dioscin significantly improved cardiac function in mice with myocardial infarction, reduced cardiac fibrosis and apoptosis, and alleviated cardiac damage by promoting angiogenesis. PMC8282240
Nude mice NOZ cell xenograft model Injection 0, 5, 10 mg/kg Every 3 days for 25 days To evaluate the inhibitory effect of Dioscin on NOZ cell xenograft tumors PMC5485633
Nude mice Osteosarcoma xenograft model Oral 60 mg/kg Once daily until the end of the experiment Dioscin significantly inhibited the growth of osteosarcoma xenografts without obvious side effects PMC5832770
rats diethylnitrosamine-induced primary liver cancer model Oral 15, 30, 60 mg/kg once daily for 18 weeks Dioscin significantly inhibited diethylnitrosamine-induced primary liver cancer in rats, improved body weight changes, and restored serum levels of AFP, ALT, AST, γ-GT, ALP, and Ki67. PMC6433650

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.15mL

0.23mL

0.12mL

5.75mL

1.15mL

0.58mL

11.51mL

2.30mL

1.15mL

References

 

Historical Records

Categories